Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial

Taieb, Moustafa A El; Hegazy, Eisa M.; Ibrahim, Hassan; Osman, Asmaa B; Abualhamd, Manal

doi:10.1007/s00403-019-01943-8

Cited by 17 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] AA is the third most prevalent nonscarring hair loss disease. 1,2 There is no gender difference in prevalence of AA, although AA is the most common autoimmune disease in men. 2,5 AA sometimes co-occurs in patients with atopic dermatitis, thyroid disease, lupus erythmatosis, and other autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

Treatments for alopecia areata: A systematic review and network meta‐analysis

Fukumoto

Magno

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Existing guidelines form no consensus for alopecia areata (AA) treatment due to the absence of a universal standard treatment and arbitrary selection of reference arms in randomized control trials (RCTs). The aim is to identify the best treatment and to rank treatments using systematic review and network meta‐analysis. Data were extracted by the two investigators independently. Odds ratio (OR) of treatment success rate was pooled using the frequentist weighted least squares approach to random‐model network meta‐analysis. RCTs providing data of treatment success rate from PubMed, EMBASE, Web of Science, and manual search were included. About 54 RCTs consisting of 49 treatments and 3149 patients were included. Pentoxifylline plus topical corticosteroids had the highest treatment success rate compared with “no treatment,” followed by pentoxifylline alone, topical calcipotriol plus narrowband ultraviolet radiation B phototherapy, topical calcipotriol, intralesional corticosteroids, systemic corticosteroids, minoxidil plus topical corticosteroids, topical bimatoprost, psoralen ultraviolet radiation A phototherapy, and tofacitinib. Even with the network meta‐analysis, the best treatment because of independent loops and wide confidence intervals could not be identified. Treatment options above may be reasonable strategies, but further comparison is required.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatments for alopecia areata: A systematic review and network meta‐analysis

Fukumoto

Magno

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…However, long time of acting is the limitation of minoxidil, even though multiple studies have demonstrated the efficacy . With the development of new technologies, more and more lasers or lamps have been used to treat alopecia, such as ultraviolet , excimer laser/lamp , low‐level laser , erbium‐glass laser , thulium laser , and carbon dioxide laser . Recently, individual researchers have been considering 308‐nm excimer lamp to be used for treating AA by inducing apoptosis of T lymphocytes, but the effective rates had differences in studies .…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Influence Factors of 308‐nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata

Meng

Xing

et al. 2020

Lasers Surg Med

View full text Add to dashboard Cite

Background and Objectives Alopecia areata (AA) is an autoimmune disease characterized by T cell‐mediated attack on the hair follicle. Although there are a wide range of therapies, the majority of them are not satisfactory due to side effects or limited efficacy. In this study, we sought to evaluate the efficacy, influence factors, and safety of 308‐nm excimer lamp with minoxidil in the treatment of AA. Study Design/Materials and Methods This was a prospective, single‐blinded, self‐control study, using 308‐nm excimer lamp with minoxidil for the treatment of AA. One selected alopecia lesion was divided into the control and treated side. Topical minoxidil (2% solution) was used on both sides, but 308‐nm excimer lamp was only added to the treated side. The primary endpoint was the discrepancy of hair growth on each side. Results A total of 38 patients (24 males and 14 females) with AA were enrolled in this study, and 34 of them (21 males and 13 females) completed the whole treatment. Thirty‐two (94.2%) patients achieved clinical response, and 21 (44.1%) patients achieved with >50% hair regrowth on the treated side after a 12‐week treatment. The hair number and diameter on the treated side had significantly increased compared with the control side with statistical differences. Hyperpigmentation and erythema occurred on the treated side of all the patients but they were considered tolerable. Patients of younger age or with smaller area of lesion had better effect. Conclusions The 308‐nm excimer lamp with minoxidil therapy can be considered as an effective and safe treatment for single or multiple AA. Lasers Surg. Med. © 2020 Wiley Periodicals, Inc.

show abstract

“…Alopecia areata (AA) is a disorder of hair loss which has a life time incidence of about 2% [1], [2]. AA is the most common non-scarring hair loss disease after male/female pattern baldness and telogen effluvium [3], [4]. It is characterized clinically by well-demarcated single or multiple grouped macules or patches of sudden hair loss.…”

Section: Introductionmentioning

confidence: 99%

Low Level Laser versus Platelet-rich Plasma in Treatment of Alopecia Areata: A Randomized Controlled Intra-patient Comparative Study

Tawfik

Mostafa²,

Soliman

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Background: Non-scarring alopecia areata (AA) is a disease that is mediated through autoimmunity. Recently, autologous platelet-rich plasma (PRP) and photobiomodulation (PBM), commonly known as low-level laser (or light, LLLT) have been suggested to provide a valuable role in stimulating the growth of hair follicles (HF) Aim: Compare between the significance and wellbeing of PRP and LLLT in the management of AA. Patients & methodology: Thirty patients, each having three patches of AA participated in the study. Patches were assigned randomly to have one of the two treatments: PRP or LLLT. The third patch served as a control and received placebo treatment. PRP was done once weekly whereas LLLT was done 3 sessions per week for a maximum of 6 weeks. Patients were followed up at one month and three months. The thickness and density of hair were evaluated by the folliscope. Results: A noteworthy higher improvement was detected in the thickness and the density of hair in the PRP treated patches as evaluated by the folliscope and patients satisfaction. The obtained outcomes were sustained during the 12 week follow-up period in most of patients. Conclusion: PRP and LLLT could be considered as efficacious alternatives for the treatments of AA with the least morbidity in addition to a little cost profit ratio. KEYWORDS: Alopecia areata, platelet-rich plasma, folliscope, photobiomodulation, low level laser therapy.

show abstract

Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial

Cited by 17 publications

References 27 publications

Treatments for alopecia areata: A systematic review and network meta‐analysis

Treatments for alopecia areata: A systematic review and network meta‐analysis

Efficacy and Influence Factors of 308‐nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata

Low Level Laser versus Platelet-rich Plasma in Treatment of Alopecia Areata: A Randomized Controlled Intra-patient Comparative Study

Contact Info

Product

Resources

About